Nexvet Announces Publication of Two Peer-Reviewed Journal

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Nexvet Announces Publication of Two Peer-Reviewed Journal Articles Profiling Frunevetmab (NV-02) and Presentation at the Veterinary Pain Short Course Conference

DUBLIN, Ireland, July 20, 2016 (GLOBE NEWSWIRE) -- Nexvet Biopharma (Nasdaq: NVET ), a veterinary biologic therapeutics company, today announced the recent publication of two peer-reviewed papers regarding frunevetmab in the Journal of Veterinary Internal Medicine (JVIM), as well as an upcoming presentation by Nexvet’s Chief Scientific Officer Dr. David Gearing at the Veterinary Pain Short Course in San Diego, California on July 29, 2016. Frunevetmab (“NV-02”) is Nexvet’s anti-nerve growth factor (NGF) monoclonal antibody (mAb) therapy, which is being developed as a monthly subcutaneous injectable for the control of pain associated with osteoarthritis in cats.

JVIM is a leading veterinary journal and the official publication of the American College of Veterinary Internal Medicine (ACVIM), the European College of Veterinary Internal Medicine, the European College of Veterinary Neurology, and the European College of Equine Internal Medicine.

The first paper, entitled “ In Vitro and In Vivo Characterization of a Fully Felinized Therapeutic Anti-Nerve Growth Factor Monoclonal Antibody for the Treatment of Pain in Cats” was published on the JVIM website on June 15, 2016 and details how Nexvet’s proprietary platform technology, PETization, was used to design the ‘100% cat’ frunevetmab, and also describes several early proof-of-concept studies.

The second paper, entitled “ A Feline-Specific Anti-Nerve Growth Factor Antibody Improves Mobility in Cats with Degenerative Joint Disease–Associated Pain: A Pilot Proof of Concept Study” was published on the JVIM website on June 22, 2016 and focuses on a proof-of-concept study of frunevetmab in 34 cats. This study demonstrated long-lasting, statistically significant efficacy and informed the design of a further successful pilot study.

In May of 2016, Nexvet announced positive results from this larger pilot field study of frunevetmab. The study was a multi-center, placebo-controlled, randomized, double-blind field study conducted at 15 sites across the United States, and enrolled 126 cats with naturally occurring osteoarthritis. The study demonstrated statistically significant improvements over placebo on a range of endpoints and no significant adverse safety signals were observed. Nexvet is now preparing for a pivotal efficacy and field safety study of frunevetmab, anticipated to commence later in 2016.

Hyperlinks to the papers described above may be found on the frunevetmab page of Nexvet’s corporate website at www.nexvet.com .

“Nexvet is committed to scientific excellence, and part of building our leadership position in veterinary therapeutic biologic development is through sharing our strong scientific and clinical data with the wider veterinarian and clinical research community. We intend to continue building awareness of the clinical validation of PETization as a robust and rapid method for interspecies mAb translation, and the compelling advantages of biologics for the treatment of chronic conditions in companion animals,” said Dr. David Gearing, Chief Scientific Officer of Nexvet.

On a related matter, Nexvet is pleased to announce that Dr. Gearing will present a session on nerve growth factor as a target for controlling chronic pain in companion animals at the Veterinary Pain Short Course, which is a collaborative event hosted by UC San Diego's School of Medicine, the International Veterinary Academy of Pain Management, and the American College of Veterinary Anesthesia and Analgesia.

About Nexvet ( www.nexvet.com )

Nexvet is a veterinary biologic therapeutics company focused on transforming the therapeutic market for companion animals, such as dogs and cats, by developing and commercializing novel, species-specific biologics. Nexvet’s proprietary PETization™ platform is designed to rapidly design monoclonal antibodies (mAbs) that are recognized as “self” or “native” by an animal’s immune system, a property Nexvet refers to as “100% species-specificity.” Nexvet’s product candidates also build upon the safety and efficacy data from clinically tested human therapies, thereby reducing clinical risk and development cost.

Nexvet is leveraging diverse global expertise and incentives to build a vertically integrated biopharmaceutical company, which conducts drug discovery in Australia, conducts clinical development in the United States and Europe and conducts biomanufacturing in Ireland.

Forward-looking statements

This press release contains forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward looking statements consist of all statements other than statements of historical fact, including statements regarding our future results of operations and financial position, results of any current or future pivotal safety and efficacy study, future expenditures relating to our lead product candidates, time for completion of any of our studies or facilities upgrades, ability to develop our pipeline of product candidates, business strategy, prospective products, ability to successfully manufacture our own product candidates, ability to meet conditions for the receipt of government grants, time for regulatory submissions or ability to qualify for conditional licensure or obtain product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of current and anticipated products. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward looking statements. The words “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “plan,” “potential,” “predict,” “project,” “position,” “seek,” “should,” “target,” “will,” “would,” or the negative of these terms or other similar expressions are intended to identify forward looking statements, although not all forward looking statements contain these identifying words. These forward looking statements are based on current expectations, estimates, forecasts and projections about our business and the industry in which we operate, and management’s beliefs and assumptions are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors. Factors that could cause actual results to differ materially from our expectations expressed in this report include those summarized under Risk Factors in our reports on Forms 10-Q and 10-K and the other documents we file from time to time with the Securities and Exchange Commission. Given these risks and uncertainties, you should not place undue reliance on these forward looking statements. Also, forward looking statements represent management’s beliefs and assumptions only as of the date of this press release. Except as required by law, we do not intend, and undertake no obligation, to revise or update these forward looking statements, or to update the reasons actual results could differ materially from those anticipated in these forward looking statements, even if new information becomes available in the future.

Further information: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 cknoll@bplifescience.com Media Jessica Burns Berry & Company Public Relations +1 212-253-8881 jburns@berrypr.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

LA Hospitals Shine in Pulmonary Excellence Nationwide

Updated Category News Views 135

Los Angeles Community Hospitals' Recent Recognition You ever stroll into a hospital and wonder if you’re really getting the best care? Well, the folks over at Los Angeles Community Hospitals, covering LA, Norwalk, and Bellflower, just got a big nod from Healthgrades—yeah, the site everyone's checking to find decent healthcare options. They’ve landed among the top...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 143

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 152

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Disney+ Teams Up with Tiff's: Blue Cookie Debut

Updated Category News Views 182

A Sweet Collaboration on the Horizon If somebody had told me that cookies could conjure up excitement equivalent to a TV show's new season, I'd have laughed. But here we are—Disney+ and Tiff's Treats are cooking up a storm with blue chocolate chip cookies to celebrate 'Percy Jackson and the Olympians' Season 3 premiere. The Cookie That Packs a Punch Forget ordinary...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 239

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Austin Rattler Event Revamps With Two-Day Off-Road Bash

Updated Category News Views 42

Austin's Off-Road Bash Kicks Up Dust in Hill Country It's not just another grind in the biking and running world; the Life Time Austin Rattler's gone off the reservation pushing the pedals and the pace across the rugged terrain of Texas Hill Country. Here's to muscles burning and soles slapping the dirt for two straight days, all in the name of challenging nature's best....

Continue Reading
Ross Pools Joins Forces with Florida Panthers in 2026

Updated Category News Views 69

An Unlikely Team-Up: Pools and Hockey Well, here's one for the books: a South Florida pool company hitching its wagon to an NHL team. Ross Pools, the folks who’ve been carving out backyard oases in the sizzling Florida sun for over two decades, are now officially aligned with the Florida Panthers. Yeah, the same Panthers that snatched the Stanley Cup not once but twice...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 242

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
Kinross Gold Faces Class Action Over Misleading Forecasts

Updated Category News Views 125

A Golden Opportunity Gone Wrong Well, it looks like Kinross Gold Corporation (NYSE: KGC) has stuck its foot in it again. This time, they're in hot water over claims that don't exactly hold up under scrutiny. If you're holding KGC, you've probably heard about the fresh class action lawsuit alleging they misled investors about their production targets. Naturally, the...

Continue Reading
Tigo Energy Faces Lawsuit: Key Details for Investors

Updated Category News Views 123

Tigo Energy Inc.'s Troubles: A Stock Drop and Legal Woes You see, not every day do you wake up to find your investment taking a nose dive by 36.76%. But that’s exactly what happened to Tigo Energy, Inc. (NASDAQ: TYGO) after some shaky announcements. A Rollercoaster for Investors On August 4, 2026, Tigo hit investors with a one-two punch: revised financial outlook and...

Continue Reading

Top 5 Most Recently Viewed Articles

GIGABYTE Unveils Compact NVIDIA GeForce RTX 50 Series GPUs

Updated Category News Views 348

GIGABYTE Shines at CES with Revolutionary Graphics Card Launch The latest unveiling from GIGABYTE, a leader in innovative computer hardware, features their NVIDIA GeForce RTX™ 50 Series graphics cards. These models, including the GeForce RTX™ 5090, RTX™ 5090 D, RTX™ 5080, RTX™ 5070 Ti, and RTX™ 5070, promise to elevate gaming and creative experiences...

Continue Reading
EssilorLuxottica's Strategic Share Buyback Announcement Details

Updated Category News Views 246

EssilorLuxottica: Share Buyback Update Disclosure of transactions in own shares EssilorLuxottica has recently informed the public about its share buyback activities, following the authorization from its Annual Shareholders’ Meeting held on April 30, 2024. This initiative reflects the company's commitment to maintaining a healthy and robust stock market presence. Recent...

Continue Reading
Aker BP Announces Ex-Dividend Payment of USD 0.63 Today

Updated Category News Views 185

Understanding Aker BP's Ex-Dividend Payment Aker BP ASA has officially announced that its shares will commence trading ex-dividend today, marking a significant moment for investors. The ex-dividend amount is set at USD 0.63 per share, equivalent to NOK 6.36193. This announcement is crucial for shareholders looking to understand their financial returns from this reputable...

Continue Reading
PL Developments Secures FDA Nod for Omeprazole and Debt Restructure

Updated Category News Views 331

PL Developments Reaches Major Milestones With FDA Approval PL Developments (PLD), a leader in the healthcare sector, recently announced two substantial achievements: the FDA's approval for its Omeprazole OTC ANDA and the successful refinancing of its corporate debt. These milestones mark significant advancements in the company's ongoing efforts to innovate and grow....

Continue Reading
Akari Therapeutics Gears Up for Innovations in ADC Payloads

Updated Category News Views 237

Akari Therapeutics Gears Up for Innovations in ADC Payloads Akari Therapeutics, Plc (NASDAQ: AKTX), is making strides in the oncology biotechnology field, particularly with its progressive advancements in antibody drug conjugates (ADCs). Recently, the company released an insightful segment of the CEO Corner, which provides a comprehensive update on its initiatives and...

Continue Reading